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The phase 1 clinical trial of systemic Targeted Alpha Therapy for metastatic melanoma has shown that solid
tumours can be regressed by alpha radiation. However, patient blood vessels and lymphocytes inevitably received a
background radiation from non-targeted alpha decays in the blood circulation. To determine the toxicity of alpha
particle to normal tissue capillaries and peripheral blood lymphocytes, capillary and lymphocyte models were
established with Geant4 Monte Carlo microdosimetry technique. The specific energy deposited in a capillary
endothelial cell nucleus or lymphocyte nucleus per radioactive decay and the cell survival rates were calculated for
the source constrained in the vessel. The specific energy to lymphocytes depends on the type of blood vessels, with
survival rates between 89% and 98%. The relationship between calculated specific energy and micronuclei data
obtained in a clinical trial was determined, further establishing this technique as a biological dosimeter for Targeted
Alpha Therapy. The 2 cGy dose to the capillary endothelial cell nucleus was found to be negligible. These results
show that systemic Targeted Alpha Therapy is safe for the function of lymphocytes and normal tissue capillaries.
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I. Introduction 1
Melanoma lesions experienced marked regression after
systemic Targeted Alpha Therapy (TAT) in several patients
of a phase 1 clinical trial.1) In this study, the melanoma
specific monoclonal antibody 9.2.27 was chelated to alpha
emitter 213Bi. This alpha-immunoconjugate 213Bi- cDTPA9.2.27 (AIC) was systematically administrated into patients
to kill isolated cells and cell clusters, and so stop the
development of lethal metastatic cancer. While adverse
events were not observed, the radioisotope will circulate
with blood and post a background dose to the vascular
system. This is a potential hazard and might be a stochastic
cause of secondary cancer.
Lymphocytes (LCs) in the blood and endothelial cells
(ECs) of normal capillaries are two potential victims of this
background dose and were chosen to evaluate the
non-specific background damage of the alpha irradiation.
Alpha particles have a high linear energy transfer (LET) and
can deposit a highly variable dose to these cells. Thus a
microdosimetry technique is essential to investigate the
physical properties of TAT.
The Geant4 Monte Carlo code was adopted to build up
LC and capillary EC models. Because 9.2.27 is not a specific
antibody for healthy LC and ECs, the non-targeted source
was assumed to be uniformly distributed in the blood. The
single-hit specific energy distribution of radioisotope source
213
Bi was calculated for each model and the specific energy
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for LCs was determined in different size vessels.
Direct exposure to ionizing radiation induces an increase
in the frequency of apoptosis and micronucleus (MN)
formation. The cytokinesis-block micronucleus assay allows
these MN to be counted, providing an in situ biological
dosimeter.2) In this study, we evaluated the MN frequency in
peripheral blood LCs after in vitro incubation with the AIC.
A conversion function between specific energy for LC and
the number of MN was developed. Further, the simulation
results were applied to quantitatively analyse patient safety
in the phase 1 clinical trial of systemic TAT for melanoma.

II. Method
1. Geant4 Monte Carlo Simulation
Geant4 is a Monte Carlo Toolkit for the simulation of the
passage of particles through matter.3) In this study Geant4
version 9.3 was adopted to identify the critical physical
features of radiation in the LC and EC nucleus. The Geant4
Low Energy Physics was selected to model the particle
interaction with the water materials involved in the
experiment. The threshold of production for secondary
particles was 250 eV.
A useful source of alphas is 213Bi with half‑life of 45.6
minutes and was chosen in the clinical trial.1) In this study,
beta and gamma decay products from 213Bi were ignored as
their contribution to the dose is negligible.4) Only alpha
particles, with intensities of 98% at 8.4 MeV and 2% at 5.8
MeV, were included.
The energy deposition ε is a fundamental parameter in
microdosimetry arising from a single traversal of the target
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volume. The energy deposition of an alpha particle and its
secondary particles in the LC and EC nucleus were recorded
and processed.
The coordinates of intersection between the alpha particle
track and the cell nucleus were recorded. Pa is entry
coordinate and Pb the exit coordinate. Here we assume alpha
particle track is straight. The chord length l of a traversal is:
μm
(1)
l = Pb – Pa
The LET is given by:
keV/μm
(2)
LET = ε / l
The specific energy z is the energy deposition (Joule) per
unit mass (kg) of the target:
Gy
(3)
z = ε/m
The event distribution was calculated for deposited
energy, LET and specific energy. The weighted average
values were calculated from the event distributions.
2. Lymphocyte Model
The LC and its nucleus can be modeled as two eccentric
ellipsoids. The morphometric scheme of a LC is presented in
Fig. 1.5) The long axis are 7.33 μm for the cell and 6.2 μm
for its nucleus. The ratio of major and minor axes of LCs
and nucleus is 1.1 and 1.2 respectively. The displacement of
the nucleus is assumed to be 0.3 μm and the mean value for
off-orientation is about 10°. The nuclear density is assumed
to be 1.0 g/cm3. LC cytoplasm and surrounding blood
material were assumed as liquid water.

Activity in the blood would give the vasculature system a
background radiation dose. To determine whether the
background dose would damage the capillary ECs, alpha
particles were randomly emitted from within the capillary
lumen.

III. Result
1. Lymphocyte and Capillary EC Models
The average deposited energy of an alpha particle when it
traverses the LC and EC nuclei was 274 and 226 keV; the
mean LET was 73 and 66 keV/μm respectively. The specific
energy per traversal over the nucleus target volume was 0.5
Gy for the LC model and 0.4 Gy for the capillary EC model.
The energy deposition ε was higher for the LC because the
size of its nucleus was larger allowing more deposited
energy. The probability of traversal in LC model was
calculated in a capillary source setting. The results for TAT
microdosimetry for the LC and capillary EC models are
given in Table 1.
Table 1 Average Parameters in TAT microdosimetry
Model
Lymphocyte
Capillary

ε per
traversal
(keV)

LET
(keV/μm)

z per
traversal
(Gy)

Probability
of traversal
(%)

274
226

73
66

0.5
0.4

2.7
2.8

Mean z
per
decay
(cGy)
1.4
1.1

The probability distribution for the specific energy within
the target volume from single traversal is referred to as the
single-hit specific energy distribution spectrum, as shown in
Fig. 3.

Fig. 1 Morphometric scheme of Lymphocyte Model

The LC was positioned in vessels with 50μm length and
various diameters.
3. Capillary Endothelial Cell Model
The normal tissue capillary EC geometry was constructed
by building up a 50 μm long, 8 μm inner and 10 μm outer
6)
diameter tube with an oval nucleus on the internal wall
(Fig. 2). The EC nucleus was an ellipsoid with radius axes of
5×2.35×1.85 μm (the radius taken from transmission
electron micrographs7) of endothelial nuclei measurement)
and with a density of 1.0 g/cm3. The nucleus was oriented
parallel to the axis of the blood vessel. EC cytoplasm, blood
and peripheral cells material were assumed as liquid water.

Fig. 2 Capillary geometry of hollow cylinder with an ellipsoidal
cell nucleus in the wall

Fig. 3 Normalized single-hit specific energy distribution in the
LC and capillary EC model

When 213Bi atoms are near the boundary of a vessel, about
half of the emitted alpha particles escape the blood vessel.
This boundary effect has to be taken into account. In this
case a LC was placed at the center of a 50 µm long vessel
with the following diameters: arteriole (30 µm), capillary (8
µm) and venules (20 µm).6) When the vessel radius exceed
the 80 µm range of alpha particles, the boundary effect
abates because the particles emitted near vessel wall won’t
have opportunity to reach the LC nucleus.
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The administered AIC in the melanoma clinical trial
contained up to 25 mCi of 213Bi.8) The total number of 213Bi
atom (t1/2=45.6 min =2736 sec) present in the 25 mCi
(9.25×108 Bq) was
Ntotal-atom = A/λ = 9.25×108/(0.693/2736) = 3.65×1012 (4)
in which λ is a decay constant calculated by 0.693/isotope
half life.
The 213Bi concentration (CBi) was constatnt in each vessel
so the total number of disintegration of above three vessels
was different. Assume there is 5 liters of blood in the body,9)
then:
(5)
CBi = 3.65×1012/5L =7.3×10-4 atom/µm3
The vessel diameter determines the number of traversals
(Table 2). The background dose for one central LC nucleus
was 2.5 cGy in capillary, 9.6 cGy in venule and 15.1 cGy in
arteriole (Table 2). The traversal number was the least in the
capillary because the number of 213Bi sources is lower.
Table 2 Number of traversal and z in different kind of vessels
Vessel
arteriole
capillary
venule

Traversal
0.29
0.05
0.19

z (cGy)
15.1
2.5
9.6

2. Lymphocyte Micronuclei (MN)
Cytokinesis-blocked micronucleus assay allows the
evaluation of radiation induced cytogenetic damage to LCs
after ionizing radiation.10) The AIC 213Bi- cDTPA -9.2.27
was used in the clinical trial. 9.2.27 is an IgG2a mouse
monoclonal antibody, reactive with the melanoma MCSP
antigen, which is not expressed on LCs. As such, there is no
significant targeting effect with the AIC. Blood from three
healthy human volunteers was collected and LCs were
isolated and irradiated in vitro with activities of 10–1200
kBq of 213Bi- cDTPA -9.2.27.11) The MN frequency was
determined by the analysis of 1000 binucleated cells per
subject. The total activity and number of MNs formed is
shown in Table 3.
Table 3 Average MN, total z vs activity
Activity
of 213Bi
(kBq/mL)
0
15
30
60
90
120
150
300
600

Average
MN12)

Total
z (Gy)

20
38
70
69
164
210
220
391
676

0
0.1
0.2
0.4
0.6
0.8
1.0
1.9
3.8

The specific energy to one LC nucleus was derived by
Geant4 simulation calculation in the third column.
A quadratic relationship between specific energy and
number of MN was observed and is shown in Fig 4. The
fitted equation is established as formula 6.
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Fig. 4

z and MN response relationship

z = 0.0003MN2 + 0.4MN - 3.4
(6)
This function built up a bridge between injected activity,
specific energy and biological endpoints. It can be used to
predict the biological effective dose by counting number of
MN in 1000 binucleated cells under the light microscope.
3. Dose to Capillary EC Nucleus
In the clinical trial case, the number of 213Bi atoms in the
volume of one capillary lumen volume of 2.5×10-12 liter
(πr2•L) was:
NBi-in-lumen = Ntotal-atom × volume ratio = 3.65×1012 ×
(7)
(2.5×10-12/5) = 1.8
The actual background dose to the EC nucleus was
calculated by multiplying the specific energy of single 213Bi
decay and the number of 213Bi atoms in the lumen:
Dose per-EC-nucleus = Dose per-traversal × NBi-in-lumen
= 1.1 cGy ×1.8 = 2 cGy
(8)
The background dose for one normal tissue capillary
nucleus was 2 cGy. The small number of decays gave a large
standard deviation of 1.4 cGy.
4. Cell Survival Fraction
The specific energy data can be used to estimate the
fraction of cell survivors by a biological cell inactivation
model.13-15) The cell surviving fraction following alpha
particle irradiation is given by:
(9)
S = e -D/D0
where D0 is the dose to yield a 37% surviving fraction.
Alpha survival experiments gave D0 =1.4-1.7 Gy.16) Note
that alpha cell survival curves are relatively insensitive to the
cell cycle or oxygen status.
On this basis, for 25 mCi injected activity, the 2 cGy
background dose corresponds to about 99% survival rate for
normal capillary ECs and 2.5 cGy to 15.1 cGy dose (Table 2)
corresponds to 89% ~ 98% survival rates for LCs. A small
loss of ECs and LCs is not significant.

IV. Discussion
In the phase 1 trial of systemic Targeted Alpha Therapy
for metastatic melanoma, the alpha-immunoconjugate is
administrated intravenously. This systemic therapy can do
harm to blood cells and endothelial cells. However, after the
alpha-immunoconjugates spread throughout the whole body,
the radionuclei density is small in the 5 L blood pool. The
size of blood cells and endothelial cells is too small for the
direct measurement of absorbed dose by solid state
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dosimeter. The aim of Monte Carlo microdosimetry is to
calculate dose at the micrometer scale. The specific energy
to the lymphocyte and endothelial cell nucleus was
calculated by the Geant4 Monte Carlo simulation based on
physical emission characteristics, on the properties of the
medium and cell morphometry.
Cell geometry can have an important influence on the
single-cell microdosimetry result. The model parameters in
this study were all taken from biological measurements
rather than simple physics model. The total activity in the
blood was assumed to be uniform and there is no
radioisotope clearance, so as to give a certain density of
213
Bi.
A quadratic fitting function of specific energy to
lymphocyte and number of micronuclei was established.
Because of the simplicity of the technique and rapid
assessment of the binucleated cells, we suggest the use of the
micronucleus measurement of patient’s blood as a biological
dosimeter for systemic Targeted Alpha Therapy.
Loss of lymphocyte and endothelial cell is not significant
but further study is needed to investigate how systemic
Targeted Alpha Therapy affects on bone marrow stem cells.
For tumors, because of the targeting accumulation effect,
the alpha-immunoconjugate dose is lethal to tumor
endothelial cell (unpublished data). For endothelial cells in
normal tissue, the short 45.6 minutes half life of 213Bi and
the low administrated radioactivity limited the absorbed dose
to an acceptable point. Therefore, we conclude that the
background dose to patients in Targeted Alpha Therapy is
safe.
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